Company: SUPN
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001356576-25-000055
Chunk: 154

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 8
Chunk 154
---
N-820, partially offset by the increase in clinical program costs on SPN-817. 

Selling, General and Administrative Expenses

The following table provides information regarding our selling, general and administrative (SG&A) expenses during the periods indicated (dollars in thousands):

Three Months EndedJune 30,ChangeSix Months EndedJune 30,Change20252024AmountPercent20252024AmountPercentSelling and marketing $65,130 $58,804 $6,326 11%$128,408 $118,371 $10,037 8%General and administrative 28,421 27,100 1,321 5%55,087 54,049 1,038 2%Total $93,551 $85,904 $7,647 9%$183,495 $172,420 $11,075 6%

Selling and marketing expenses were $65.1 million and $58.8 million for the three months ended June 30, 2025 and 2024, respectively. The increase was primarily due to higher professional and consulting expenses and employee-related expenses. 

Selling and marketing expenses were $128.4 million and $118.4 million for the six months ended June 30, 2025 and 2024, respectively. The increase was primarily due to timing of product sample shipments, higher professional and consulting expenses and employee-related expenses. 

General and administrative expenses were $28.4 million and $27.1 million for the three months ended June 30, 2025 and 2024, respectively.  General and administrative expenses were $55.1 million and $54.0 million for the six months ended June 30, 2025 and 2024, respectively.

Amortization of Intangible Assets

Amortization of intangible assets was $20.8 million and $20.1 million for the three months ended June 30, 2025 and 2024, respectively. Amortization of intangible assets was $40.6 million and $40.2 million for the six months ended June 30, 2025 and 2024, respectively. The increase was primarily due to ONAPGO amortization expense in 2025 offset by amortization expense in 2024 for Oxtellar XR and Namzaric intangible assets, which were being fully amortized in 2024. ONAPGO was previously accounted for as an indefinite